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A previous linkage study provided evidence for a prostate cancer–susceptibility locus at 1q24-25. Subsequent reports
in additional collections of families have yielded conflicting results. In addition, evidence for locus heterogeneity
has been provided by the identification of other putative hereditary prostate cancer loci on Xq27-28, 1q42-43, and
1p36. The present study describes a combined analysis for six markers in the 1q24-25 region in 772 families
affected by hereditary prostate cancer and ascertained by the members of the International Consortium for Prostate
Cancer Genetics (ICPCG) from North America, Australia, Finland, Norway, Sweden, and the United Kingdom.
Overall, there was some evidence for linkage, with a peak parametric multipoint LOD score assuming heterogeneity
(HLOD) of 1.40 ( ) at D1S212. The estimated proportion of families (a) linked to the locus was .06 (1-P = .01
LOD support interval .01–.12). This evidence was not observed by a nonparametric approach, presumably because
of the extensive heterogeneity. Further parametric analysis revealed a significant effect of the presence of male-to-
male disease transmission within the families. In the subset of 491 such families, the peak HLOD was 2.56 (P =
) and a = .11 (1-LOD support interval .04–.19), compared with HLODs of 0 in the remaining 281 families..0006
Within the families with male-to-male disease transmission, a increased with the early mean age at diagnosis (!65
years, a = .19, with 1-LOD support interval .06–.34) and the number of affected family members (five or more
family members, a = .15, with 1-LOD support interval .04–.28). The highest value of a was observed for the 48
families that met all three criteria (peak HLOD = 2.25, , , with 1-LOD support interval .08–.53).P = .001 a = .29
These results support the finding of a prostate cancer–susceptibility gene linked to 1q24-25, albeit in a defined
subset of prostate cancer families. Although HPC1 accounts for only a small proportion of all families affected by
hereditary prostate cancer, it appears to play a more prominent role in the subset of families with several members
affected at an early age and with male-to-male disease transmission.
Introduction
Prostate cancer has significant international public-
health importance, with a worldwide estimate of
239,000 deaths resulting from this disease annually
(WHO); in the United States, it is the most common
malignancy diagnosed in men. With over 175,000 new
cases diagnosed annually (Landis et al. 1999), prostate
cancer causes a tremendous social and economic burden
to patients, their families, and society. Despite the sig-
nificance of the disease, progress in understanding the
molecular determinants of prostate cancer susceptibility
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is still in the initial stages. Genetic epidemiological stud-
ies supporting the existence of hereditary forms of pros-
tate cancer have led to the initiation of genomewide
searches for loci contributing to hereditary prostate can-
cer. A previous genomewide scan for hereditary prostate
cancer (HPC) loci in prostate cancer families ascertained
at the Johns Hopkins University and Umea˚ University
in Sweden resulted in an indication of a prostate
cancer–susceptibility locus at 1q24-25 (HPC1 [MIM
601518]). The maximum multipoint parametric LOD
score was 3.65 at D1S2883 (Smith et al. 1996). There
was significant evidence for locus heterogeneity, with an
estimate of 34% of the families being linked to HPC1
(LOD assuming heterogeneity [HLOD] = 5.43 at
D1S422). Subsequent stratification analysis revealed
that families linked to HPC1 tended to have an early
mean age at diagnosis and a large number of affected
family members (Gro¨nberg et al. 1997). The maximum
HLOD was 4.88 for 40 families whose members had a
mean age at diagnosis of !65 years, but the maximum
HLOD was only 0.28 for 39 families whose members
had a mean age at diagnosis of 65 years. The maxi-
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mum HLOD was 5.45 for 45 families with five or more
affected members in a family, but it was only 0.18 and
0.83 for families with three affected members (10 fam-
ilies) and four affected members (24 families), res-
pectively.
Although two subsequent studies have corroborated
linkage to HPC1 (Cooney et al. 1997; Hsieh et al.
1997), three additional studies found no clear evidence
for HPC1-predisposed disease within their study pop-
ulations (McIndoe et al. 1997; Berthon et al. 1998; Eeles
et al. 1998). Cooney et al. (1997) reported a linkage
study of 1q24-25 in 59 families affected by prostate
cancer, each with two or more affected individuals. The
peak nonparametric linkage (NPL) score was 1.58 at
D1S466 ( ) in the 59 families, but was 1.72P = .057
( ) in the subset of 20 families that met the cri-P = .045
teria for HPC—operationally defined as having three or
more affected individuals within one nuclear family, af-
fected individuals in three successive generations, or
clustering of two or more individuals affected before
age 55 years. Hsieh et al. (1997) reported further evi-
dence to support HPC1. In 92 unrelated families with
three or more affected individuals, the NPL score was
1.71 ( ). The evidence for linkage was strongerP = .046
in the 46 families with mean age at diagnosis of !67
years. The NPL score was 2.04 ( ). McIndoe etP = .023
al. (1997) reported no evidence for linkage in this re-
gion, in 49 families with a high risk for prostate cancer,
either by a parametric LOD score approach assuming
homogeneity or by nonparametric analysis. There was
also no evidence for linkage in the 18 families whose
members had an early mean age at diagnosis (!65
years). Berthon et al. (1998) reported results of a ge-
nomewide screen as well as results from the 1q24-25
region in 47 French and German families. For the three
markers in the 1q24-25 region, they found negative
two-point LOD scores, assuming a dominantmodel. No
results, however, were reported for the families whose
members had an early age at diagnosis or a large number
of affected individuals. Eeles et al. (1998) reported a
linkage study of 1q24-25 in 136 families associatedwith
prostate cancer ascertained in UnitedKingdom,Quebec,
and Texas, 76 of which had three or more affected in-
dividuals. They found negative NPL scores in this region
in the total sample, but they found positive NPL scores
in a subset of 35 families with four or more affected
members.
Recently, a prostate cancer–susceptibility gene linked
to the Xq27-28 region (HPCX [MIM 300147]) was
reported in a combined study population of 360 families
affected by HPC collected at four different sites inNorth
America, Finland, and Sweden (Xu et al. 1998). The
peak two-point LOD score was 4.6 at DXS1113, and
the peak multipoint LOD score was 3.85 between
DXS1200 and DXS297. Significant evidence for locus
heterogeneity was observed. The proportion of families
linked to HPCX was estimated to be 16% in the com-
bined study population and was similar in each separate
family collection. The linkage of a prostate-cancer gene
to the X chromosome is consistent with the results of
several population-based studies suggesting an X-linked
mode of inheritance of prostate cancer (Woolf 1960;
Hayes et al. 1995; Monroe et al. 1995; Narod et al.
1995). Although further replication studies in indepen-
dent populations are warranted, this finding provides a
unique tool to facilitate a locus heterogeneity study; that
is, families can be stratified into two subgroups before
performing linkage analysis, with one group of families
being consistent with an X-linked mode of inheritance
(without male-to-male disease transmission within a
family), and the other group of families with male-to-
male disease transmission within a family. By using this
approach, evidence for HPC1 was strengthened in 79
HPC families ascertained at the Johns Hopkins Hos-
pital. The maximum HLOD was 4.27 in 49 families
with male-to-male disease transmission but was only
0.43 in 29 families without male-to-male disease trans-
mission (one family’s mode of transmission could not
be unequivocally classified as male to male).
Further evidence for locus heterogeneitywas observed
in two other prostate cancer linkage studies. Berthon et
al. (1998) reported a linkage (PCaP [MIM 602759]) at
1q42-43 in 47 French and German prostate cancer fam-
ilies, and most recently, Gibbs et al. (1999) reported
evidence for a third locus on chromosome 1 (1p36
[MIM 603688]) that predisposes its carrier to both
prostate and brain cancer.
The observations in all of these studies emphasize the
common set of obstacles for linkage detection in
HPC—most prominently, a significant degree of locus
heterogeneity, a high phenocopy rate, and the late age
at onset of the disease. Because of the significant degree
of locus heterogeneity, any single HPC locus may be
responsible for only a small proportion of families af-
fected by HPC in general, although a single locus may
be responsible for a larger proportion of families af-
fected by HPC in different family collections or in de-
fined subsets of a study population or sample. The high
age-dependent phenocopy rate in prostate cancer fur-
ther masks the ability to detect HPC loci. These barriers
are compounded by the late age at onset of the disease,
making it difficult to ascertain families that may provide
information for linkage studies. Therefore, it is difficult
to have sufficient power to detect and localize HPC loci
in a single data set with a limited number of HPC fam-
ilies. For this reason, the International Consortium for
Prostate Cancer Genetics (ICPCG) was formed to es-
tablish a larger data set of HPC families. Currently, data
from 772 prostate cancer families ascertained from
seven countries are available for linkage analysis. This
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is a valuable resource for identification and localization
of prostate cancer–susceptibility loci.
The present report describes the results of the com-
bined analysis for linkage data on six markers in the
1q24-25 region using the resource of 772 families af-
fected by HPC from ICPCG. Specifically, four questions
were addressed: (1) Is there any evidence for link-
age between the prostate cancer–susceptibility locus
(HPC1) and markers at the 1q24-25 region in the over-
all 772 HPC families? (2) Is theHPC1 locus more prom-
inent in the subset of families with male-to-male disease
transmission? (3) Is the HPC1 locus more prominent in
families with an early mean age at diagnosis (!65
years)? (4) Is the HPC1 locus more prominent in fam-
ilies with more affected members (five or more)?
Subjects and Methods
Ascertainment of Families
Families with three or more prostate cancer cases (not
necessarily all available for genotyping) were eligible for
inclusion in this study. Families with fewer than three
cases were excluded, as they are more likely to represent
chance clustering of the disease and have little power to
detect linkage. Families were defined as having male-to-
male disease transmission when there was evidence of
paternal disease transmission in the families, including
the following: (1) presence of affected father and affected
son or sons; (2) presence of prostate cancer cases on the
paternal side of the family, with no evidence of affected
relatives on the maternal side; or (3) presence of prostate
cancer cases on the maternal side of the family and male-
to-male disease transmission on the maternal side. The
remaining families were defined as non–male-to-male
disease transmission families. They have either an un-
known mode of inheritance (insufficient data to deter-
mine inheritance pattern) or are consistent withX-linked
mode of inheritance.
The families under study in this report were collected
by a variety of research groups in several countries. The
ACTANE (Anglo, Canada, Texas, Australia, Norway,
EU Biomed) Group, which is a multinational consortium
of research groups, has members from the United King-
dom, the state of Texas in the United States, Canada,
Norway, and Australia. Families were recruited for study
in these regions.
The United Kingdom Group recruited 35 families for
study. All families were assessed for inclusion through
collaborating urologists, geneticists, or oncologists via
the British Prostate Group; 97% of the cases were clin-
ically detected, and the remaining 3% were detected
through a prostate specific antigen (PSA) screen. All re-
ports of cancer were confirmed by a histopathology re-
port or by medical records.
The Texas group recruited six families. The probands
in these families were patients referred to the University
of Texas M. D. Anderson Cancer Center in Houston,
and were subsequently diagnosed with prostate cancer.
The Canada group recruited 43 families. Fourteen
families were recruited through prostate and hereditary
cancer clinics in Montreal; two were recruited from the
Prostate Clinic in Halifax, Nova Scotia; and 27 were
recruited after an advertisement was placed inviting par-
ticipation in a prostate cancer–susceptibility gene study
in a magazine produced by the Patient Advocates for
Advanced Cancer Treatment, a prostate cancer–advo-
cate organization founded in Grand Rapids, MI. In 12
of these families, at least one affected member was as-
sessed by a PSA screen.
The Norway group studied three families. Families
were referred to the cancer genetics clinic at the Nor-
wegian Radium Hospital because of their high incidence
of prostate cancer. All cases of prostate cancer were clin-
ical presentations.
The Australia group studied 13 families. These fam-
ilies were recruited from the Risk Factors for Prostate
Cancer study, a population-based, case-control study of
1,600 cases and controls conducted in Melbourne, Syd-
ney, and Perth. Probands were aged 40–69 years and
reported a family history of prostate cancer.
The BC/CA/HI resource consists of 97 unrelated fam-
ilies in British Columbia, California, and Hawaii con-
taining three or more medically verified diagnoses of
prostate cancer in first- or second-degree relatives.
Eighty-two of these families fulfilled one or more of the
proposed criteria for families whose prostate cancer is
likely to be hereditary (i.e., three or more affected in-
dividuals within one nuclear family; affected individuals
in three successive generations; or two or more individ-
uals affected before age 55 years). Seven families were
African-American, four were Japanese-American, and
three were Chinese-American. The families were iden-
tified from several sources (described by Hsieh et al.
1997). The mean number per family of affected and
genotyped individuals was 2.6 (range 2–5), and themean
age at diagnosis of all affected individuals was 66.9 years
(67.0 years in white families, 64.1 years in African-
American families, and 69.2 years in Asian-American
families).
The 150 families in the Fred Hutchinson Family Col-
lection analysis are participating in the Prostate Cancer
Genetic Research Study (PROGRESS) and met at least
one of three criteria: three or more first-degree relatives
with prostate cancer, three generations with prostate
cancer, or two affected siblings with prostate cancer di-
agnosed at 60 years of age. PROGRESS is based in
Seattle, was initiated in 1995, has participants from
North American and several other countries, and has
ascertained eligible families through national media for
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Table 1
Markers Used in the Combined Analysis
Marker Heterozygosity
Estimated Distance
from pter
(cM)
D1S452 .75 187.5
D1S212 .80 194.9
D1S466 .77 200.7
D1S158 .89 202.8
D1S422 .76 206.6
D1S413 .76 211.8
NOTE.—The marker order and distances were
estimated from 121 HPC families ascertained at
Johns Hopkins, and they are consistent with the
LDB map (Collins et al. 1996) and the Marshfield
map.
self-referrals and through communication with urolo-
gists, prostate cancer support groups, and health-related
publications. Medical records received for 95% of the
genotyped affected men in these families confirm the
diagnosis in all but one man.
In the Johns Hopkins Family Collection, 101 families
affected by HPC were ascertained and genotyped for the
HPC1 analysis. The first 79 families with HPC were
included in the initial HPC1 report and thus are not
included in the current replication study (Smith et al.
1996). The remaining 22 families with HPC were in-
cluded. Families were ascertained at the Brady Urology
Institute at Johns Hopkins Hospital, Baltimore, MD. A
majority of these families were ascertained through re-
ferrals from physicians; some families were recruited
from earlier epidemiological studies (Carter et al. 1992)
and through news articles. Age at diagnosis of prostate
cancer was confirmed either through medical records or
from two other independent sources. All individuals in
this study gave full informed consent.
The 159 North American families in the Mayo Clinic
Family Collection were ascertained by a cancer family-
history survey sent to 15,000 men who underwent a
radical prostatectomy for clinically localized prostate
cancer in the Department of Urology at the Mayo Clinic
during 1966–1995. Further results are provided else-
where (Schaid et al. 1998). Prostate cancer diagnosis and
the age of its occurrence was confirmed through medical
records at the Mayo Clinic and elsewhere.
The 56 families reported by the Michigan Family Col-
lection are participants in the University of Michigan
Prostate Cancer Genetics Study, which was established
to define the molecular determinants of inherited pros-
tate cancer susceptibility. Collection strategy and HPC1
linkage results for a subset of these families (26 of 56)
have been previously reported (Cooney et al. 1997).
Written consent was obtained from all participants, and
research protocols were approved by the Institutional
Review Board at the University of Michigan. The di-
agnosis of prostate cancer was confirmed, in all men that
were available for genotyping, by review of pathology
reports and medical records. For the affected men who
were unavailable for genotyping, the diagnosis of pros-
tate cancer was confirmed by medical records or by two
independent family members.
In Finland, 302 families linked to prostate cancer with
two or more affected family members of the Tampere
Family Collection were identified through referrals from
physicians; family questionnaires sent to patients; a na-
tionwide registry-based search; and advertisements in
newspapers, radio, and television. Of this group, 32 fam-
ilies that met the criteria of HPC and provided infor-
mation for linkage analyses were included in this study.
Diagnosis of all prostate cancer patients was confirmed
through hospital records or from the Finnish Cancer
Registry. All individuals participating in this study gave
full informed consent.
Since 1995, families with three or more relatives af-
fected with prostate cancer have been collected at the
Department of Oncology of Umea˚ University, Sweden,
in their Umea˚ Family Collection, mainly from referrals
from urologists throughout the country. From ∼300 re-
ferrals, 40 families that provide information for linkage
analysis have been selected. Twelve of these familieswere
included in the initial report and thus were not included
in the current study (Smith et al. 1996). The remaining
28 HPC families were included. If blood samples were
unavailable, tissue samples were collected from affected
men whenever possible. Tissue samples were reviewed
by an experienced pathologist, and microdissection was
performed to separate normal and tumor tissue. For ge-
notyping, only normal tissue was used. All prostate can-
cer diagnoses in the families were confirmed by the Na-
tional Cancer Registry and medical records.
The Utah pedigrees that make up the Utah Family
Collection were ascertained from the Utah Population
Database, which combines a genealogy containing ap-
proximately eight generations of Utah pioneers and their
descendants with a cancer registry containing ∼30 years
of complete cancer registration for the state of Utah
(Skolnick et al. 1979). Approximately 298 families have
been ascertained by observation of a significant excess
of prostate cancer cases among descendants of a single
founder, with no age-at-diagnosis criteria. Of these, ge-
notyping has been completed on ∼100 pedigrees. Be-
cause the Utah pedigrees are considerably larger than
those submitted by the rest of the Consortium, they were
split into independent subpedigrees having at least three
prostate cancer cases and small enough to be analyzed
by GENEHUNTER (Kruglyak et al. 1996), the analysis
tool that had been chosen for the consortium data set.
We used an algorithm to split pedigrees; the algorithm
ascends three generations from affected individuals at
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Table 2
Genetic Models Used in the Parametric Linkage Analysis
MODELa AND
LIABILITY
CLASS
PENETRANCE
DESCRIPTIONdd Dd DD
A:
1 .001 1 1 All affected men
2 .5 .5 .5 Unaffected men aged !75 years and all women
3 .84 .37 .37 Unaffected men aged 75 years
B:
1 .00038 .0018 .0018 Affected men aged 49 years at diagnosis
2 .00061 .0084 .0084 Affected men aged 50–59 years at diagnosis
3 .0032 .03 .03 Affected men aged 60–69 years at diagnosis
4 .0082 .04 .04 Affected men aged 70–79 years at diagnosis
5 .0086 .015 .015 Affected men aged 80 years at diagnosis
6 .99981 .9908 .9908 Unaffected men aged 49 years
7 .9968 .94 .94 Unaffected men aged 50–59 years
8 .978 .75 .75 Unaffected men aged 60–69 years
9 .921 .39 .39 Unaffected men aged 70–74 years
10 .84 .12 .12 Unaffected men aged 75 years
11 .5 .5 .5 Unknown and all women
a For both model A and model B, disease-gene frequency fD = .003.
the bottom of the pedigree. Subpedigrees that were small
enough to be analyzed by GENEHUNTER were then
selected from this set. We thus created a total of 128
subpedigrees from the 81 complete pedigrees that yielded
at least one subpedigree.
Genotyping and Markers
The core markers utilized in the study are listed in
table 1. When one of the core markers was not available
in an individual family collection, two alternative ap-
proaches were used in the analysis. First, a substitute
marker was used if there was a marker within 2 cM of
the missing core marker in that family collection. Sec-
ond, a missing data point was assumed when there was
no marker data available near the missing core marker.
Although these two approaches may have had some im-
pact on the linkage results, we believe the impact will
have been small, since all the analyses were multipoint
and since we are, in essence, studying the linkage curves
(LOD and NPL) of each family in this chromosomal
region, not the marker per se.
Analytical Methods
The linkage analyses were performed by both para-
metric and nonparametric approaches, with analyses im-
plemented by the computer software package GENE-
HUNTER (Kruglyak et al. 1996). Two genetic models
describing the inheritance of a prostate cancer–
susceptibility gene were used in the parametric analyses
(table 2). Both models assumed an autosomal dominant
disease allele with an allele frequency of .003. The first
(model A) was the same model used by Smith et al.
(1996) in analysis in which the HPC1 was initially
mapped. In this model, affected men were assumed to
be carriers of a rare autosomal dominant gene with a
fixed 15% phenocopy rate, whereas all unaffected men
aged !75 years and all women were assumed to be of
an unknown phenotype. In men over age 75 years, the
lifetime penetrance of gene carriers was estimated to be
63%, and the lifetime risk of prostate cancer for non-
carriers was 16% in this age class. The second model
(model B) assumed variable penetrances and phenocopy
rates for different age groups. The age- and genotype-
specific penetrances for the 11 liability classes were de-
rived from complex segregation analysis (Carter et al.
1992) and surveillance, epidemiology, and end results
(SEER) in a fashion similar to the method used by the
Breast Cancer Linkage Consortium (Easton et al. 1993).
HLOD scores were calculated by the admixture test
(Ott 1991). In this model, two types of families are as-
sumed, one type linked to the disease locus, with a pro-
portion of a, and the other type not linked, with the
proportion 1a. A maximum-likelihood approach was
used to estimate the proportion of linked families (a) by
maximizing HLOD. The 1-LOD support interval of the
maximized a was determined as the range of a values
that gave likelihoods within 1 LOD unit of the maxi-
mized a. This approach does not accommodate the pos-
sibility that multiple prostate cancers in some members
of the families may have occurred by chance, and, there-
fore, estimates of a are crude approximations.
The NPL was calculated on the basis of observed and
expected identical-by-descent allele sharing among af-
fected relative pairs. Families were weighted equally, and
the score function “all” was used (Whittemore and Hal-
pern 1994).
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A multipoint approach was applied in the analyses to
increase the information content of the markers in HPC
families and to decrease the impact of misspecification
of marker allele frequencies on the linkage results. This
is necessary because the genotype data of the parental
generation are usually not available. A multipoint ap-
proach is also the method of choice because not all the
genotyped groups had the same core markers, although
replaced markers are, in general, in the vicinity of the
core markers. It is inappropriate to add a two-point
LOD score from each family when different markers are
used; however, it is less problematic to add the LOD
score curve of the same chromosomal region from each
family. The misspecification of the intermarker distances
may affect the linkage results, but the impact is small in
this situation because the marker distances are relatively
large (the range of intermarker recombination fractions
is .03–.08). Marker allele frequencies were calculated by
each research group on the basis of their own family
data, using the information from pedigree founders only.
The combined analysis was implemented by combin-
ing intermediate results by pedigree from each research
group. Each research group analyzed data from their
study families by use of the same procedure, intermarker
distances, software package, and options as described
above. They then submitted the LOD scores and NPL
scores by pedigree, as well as the characteristics (male-
to-male transmission, mean age at diagnosis, number of
affected members in a family) of each pedigree to the
coordinating center. For the parametric analyses, the
computer program HOMOG (Ott 1991) was used to
calculate HLOD scores. For the nonparametric method,
the overall NPL scores were calculated by the sum of
each individual pedigreeNPL score divided by the square
root of the total number of families. To ensure unifor-
mity of the analysis in each group, a test file was dis-
tributed, and the results were checked among the re-
search groups where the same results required the exact
procedure in coding liability classes and in running the
program.
LOD scores assuming heterogeneity can be converted
to a x2 ( HLOD). Although the true distri-2x = 4.6#
bution of the x2 value under the null hypothesis of no
linkage is unknown, especially in the situation of mul-
tipoint analysis, we assume that the distribution is a
mixture of one that is degenerate at zero and one that
can be approximated by the distribution of the maxi-
mum of two independent x2 variables, eachwith 1 degree
of freedom (Faraway 1993). P values were thus calcu-
lated by , where P1 is the P.5# [1 (1 P )(1 P )]1 1
value of x2 with 1 df.
When evidence for linkage was observed in the whole
sample, likelihood-ratio tests were performed to test the
hypotheses of different values of a among subsets of
families (i.e., among families with or without male-to-
male transmission, among families with five or more or
four or fewer affected members, and among families
with mean age at diagnosis !65 or 65 years). To in-
crease the power of detecting the difference, the recom-
bination fraction was restricted to be the same for both
subsets, which is the maximum-likelihood estimate of
the recombination fraction in the whole sample. A x2 =
4.6# (HLOD1HLOD2HLODtotal) is calculated that
has 1 df, where HLOD1, HLOD2, and HLODtotal are the
HLODs for the first and second subsets of families and
the whole sample, respectively.
Results and Discussion
Characterization of Families with ICPCG
A summary of the features of the 772 families studied
is presented in table 3. Some of these families have been
included in previous publications by the members of the
ICPCG. Of the 100 families from the ACTANE Group,
76 were included in the study by Eeles et al. (1998). Of
the 97 families from the BC/CA/HI Group, 92 were in-
cluded in the study by Hsieh et al. (1997). Of the 150
families from the Fred Hutchinson Group, 49 were in-
cluded in the study of McIndoe et al. (1997). Of the 56
families from the Michigan Group, 20 were included in
the study of Cooney et al. (1997). All 28 families from
the Umea˚ Group were included in the linkage report by
Gro¨nberg et al. (1999). The rest of the families—507 of
772—have not been reported in previous linkage studies
for the 1q24-25 region.
These 772 families contain an average of 4.2 affected
individuals diagnosed at an average age of 66.8 years.
Of the families, 120% had five or more affected indi-
viduals, and ∼33% had an average age at diagnosis !65
years. Sixty-four percent of the families showed evidence
of male-to-male disease transmission.
Linkage of the HPC1 Locus and Markers at 1q24-25
Multipoint HLOD scores and maximum-likelihood
estimates a for the six markers in each family collection
and in the combined sample of 772 families are shown
in table 4. Two groups had HLOD values 11; the rest
of the seven groups provided little evidence for linkage.
However, there is some evidence for linkage in the com-
bined sample. The peak HLOD was 1.4 at D1S212
( ), with an estimated proportion of linked fam-P = .01
ilies (1-LOD support interval .01–.12). Thesea = .06
results provided a weak confirmation for the linkage
between theHPC1 locus and markers at 1q24-25 region
in a subset of the HPC families. The estimated propor-
tion of families linked to HPC1 in this set of families
was much lower than the initial estimate of a = .34
(Smith et al. 1996).
It is worth noting that there are 21 African American
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Table 3
Characteristics of HPC Families in the ICPCG Combined Analysis
GROUP
TOTAL
NO. OF
PEDIGREES
TOTAL
NO. OF
INDIVIDUALS
PEDIGREES
WITH MALE-
TO-MALE
TRANSMISSION
NO. OF
AFFECTED
FAMILY
MEMBERS
PEDIGREES
WITH 5
AFFECTED
FAMILY
MEMBERS
AGE AT
DIAGNOSIS
PEDIGREES
WITH AGE AT
DIAGNOSIS
!65 YEARS
PEDIGREES
MEETING
ALL
THREE
CRITERIAa
No. % Range Mean No. % Range Mean No. % No. %
ACTANE 100 948 64 64.0 3–9 3.7 18 18.0 52.7–78.7 67.1 31 31.0 2 2.0
BC/CA/HI 97 748 41 42.3 3–6 3.3 7 7.2 53.7–80.3 66.9 37 38.1 2 2.0
Fred Hutchinson 150 2,174 83 55.3 3–10 4.3 47 31.3 50.8–78.0 65.9 56 37.3 15 10.0
Johns Hopkins 22 206 15 68.2 3–17 5.5 13 59.1 52.2–75.0 65.8 8 36.4 4 18.2
Mayo 159 1,141 113 71.1 3–11 4.4 56 35.2 47.3–76.8 66.3 62 39.0 17 10.7
Michigan 56 360 28 50.0 3–9 3.4 4 7.1 51.0–77.5 64.5 29 51.8 2 3.6
Tampere 32 1,091 13 40.6 3–6 3.6 4 12.5 58.5–77.7 68.2 8 25.0 1 3.1
Umea˚ 28 366 23 82.1 3–10 4.1 6 21.4 57.6–74.5 67.4 9 32.1 1 3.6
Utah 128 2,173 111 86.7 3–8 3.8 19 14.8 54.0–77.3 68.8 23 18.0 4 3.1
Total 772 9,207 491 63.6 3–17 4.2 174 22.5 47.3–80.3 66.8 263 34.1 48 6.2
a The three criteria are male-to-male transmission, age at diagnosis of !65 years, and 5 affected individuals per family.
families in the total 772 families (2.7%). The peak
HLOD for these families was 0.61 ( at D1S413).a = .39
The overall HLOD was unchanged when these families
were omitted from the analysis—that is, for the remain-
ing 751 families, the peak HLOD was 1.38 ( ata = .06
D1S212). We intend to further investigate the HPC1
linkage in African American families when additional
families become available.
Linkage in Families and Male-to-Male Disease
Transmission
The 772 families with HPC were stratified into fam-
ilies with male-to-male disease transmission ( ),n = 491
and families without evidence for male-to-male disease
transmission ( ). Parametric multipoint linkagen = 281
analyses were performed by using model A (table 5). For
the families with male-to-male disease transmission, the
peak HLOD was 2.56 at D1S212 ( ), withP = .0006
(1-LOD support interval .04–.19). By contrast,a = .11
families without male-to-male disease transmission did
not provide any evidence for linkage. The HLODs were
0 ( ) for all six markers. The difference in a betweena = 0
the two subsets of families was statistically significant
( , ). To exclude possible confounding2x = 4.51 P = .03
factors leading to the negative HPC1 finding in the fam-
ilies without male-to-male disease transmission, these
families were stratified by mean age at diagnosis (!65
or 65 years) and the number of affected family mem-
bers (four or fewer and five or more). No evidence for
linkage was observed in any of these groups. The
stronger evidence for linkage of the HPC1 locus and
markers at 1q24-25 in the families with male-to-male
disease transmission is consistent with the initial finding
in the 79 HPC families ascertained at Johns Hopkins
(Xu et al. 1998).
Presumably the increased evidence for linkage in this
group reflects several factors: first, there is an enrichment
in families having an autosomal dominant mode of in-
heritance, as opposed to X-chromosome or recessive
linkage; and, second, families with male-to-male trans-
mission by definition have affected individuals in more
than one generation, possibly reducing the number of
families in which the disease clustering is due to non-
genetic mechanisms (e.g., shared environment) or more
complex genetic mechanisms.
Linkage in Family Members with Early and Late Mean
Age at Diagnosis
The 772 HPC families were stratified into 263 families
that had members with an early mean age at diagnosis
(!65 years) and 509 families with members that had a
late mean age at diagnosis (65 years). Parametric mul-
tipoint linkage analyses were performed by using model
A (table 5). Families that had members with an early
mean age at diagnosis had a peak HLOD of 1.32 at
D1S212 ( ), with (1-LOD support intervalP = .01 a = .11
.02–.22). Families that had members with a later age at
diagnosis had a peak HLOD of 0.39 at the same marker
( ), with (1-LOD support interval .01–P = .16 a = .04
.12). The difference in the a values between the two
subsets of families, however, was not statistically signif-
icant ( , ). When the stratified analysis2x = 1.43 P = .23
was limited to the 491 HPC families with male-to-male
disease transmission, the 161 families that had members
with an early mean age at diagnosis had a peak HLOD
of 2.28 at D1S212 ( ), with (1-LOD sup-P = .001 a = .19
port interval .06–.34), whereas the 330 families that had
members with a late mean age at diagnosis had a max-
imized HLOD of 0.79 at D1S212 ( ), withP = .05 a =
(1-LOD support interval .01–.16). The difference in.07
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Table 4
Parametric Multipoint Analysis (LOD Assuming Heterogeneity, Model A)
GROUP (NO. OF FAMILIES)
D1S452 D1S212 D1S466 D1S158 D1S422 D1S413
HLOD a HLOD a HLOD a HLOD a HLOD a HLOD a
ACTANE (100) .03 .06 .05 .05 .03 .05 .03 .04 .06 .06 .01 .03
BC/CA/HI (97) .28 .10 .16 .07 .00 .00 .00 .00 .00 .00 .00 .00
Fred Hutchinson (150) .00 .00 .01 .01 .08 .04 .05 .03 .00 .00 .00 .00
Johns Hopkins (22) .00 .00 .35 .20 .4 .20 1.19 .32 1.16 .31 1.1 .32
Mayo (159) .12 .04 .12 .04 .15 .20 .01 .01 .09 .03 .29 .07
Michigan (56) .07 .09 .1 .09 .19 .12 .12 .09 .06 .07 .10 .10
Tempere (32) .00 .00 .00 .00 .00 .00 .00 .00 .00 .00 .00 .00
Umea˚ (28) .03 .07 .12 .14 .20 .17 .37 .21 .22 .17 .15 .16
Utah (128) 1.55 .15 1.32 .13 .88 .11 .56 .08 .06 .06 .02 .01
Combined (772) 1.00 .06 1.40 .06 .76 .05 .41 .03 .25 .03 .34 .03
the a values between the two subsets of families was not
statistically significant ( , ). These results2x = 2.35 P = .12
suggest a trend: families affected by HPC with members
that have an early age at diagnosis, especially in the
families with male-to-male disease transmission, are
more likely to be linked to HPC1 than are families not
meeting these criteria. This effect of age at diagnosis is
consistent with earlier findings by Gro¨nberg et al.
(1997).
Age at diagnosis for prostate cancer is a problematic
variable in that, in some cases, it is strongly related to
age at first screening for the disease, particularly since
the widespread use of PSA began over a decade ago (at
least in North America). As the populations studied here
vary widely with respect to frequency of disease screen-
ing and testing by PSA, age at diagnosis is an inconsistent
indicator of age at onset. For this reason, until a more
standardized approach is implemented, the impact of age
at diagnosis on the linkage result across different study
populations is difficult to fully evaluate.
Effect of Number of Affected Individuals in Families
The 772 HPC families were stratified into 174 families
with five or more affected family members and 598 fam-
ilies with four or fewer affected family members. Par-
ametric multipoint linkage analyses were performed by
using model A (table 5). Families with five or more af-
fected family members had a peak HLOD of 1.11 at
D1S212 ( ), with (1-LOD support intervalP = .02 a = .09
.01–.21). Families with four or fewer affected family
members had a peak HLOD of 0.42 at the same mar-
ker ( ), with (1-LOD support intervalP = .15 a = .05
.01–.13). The difference in the a values between the two
subsets of families, however, was not statistically signif-
icant ( , ). When the stratified analysis was2x = .60 P = .44
limited to the 491 families with male-to-male disease
transmission, the 141 families with five or more affected
family members had a peak HLOD of 2.01 at D1S212
( ), with (1-LOD support interval .04–P = .002 a = .15
.28), whereas 350 families with four or fewer affected
family members had a maximized HLOD of 0.71 at
D1S212 ( ), with (1-LOD support intervalP = .07 a = .08
.01–.19). These results suggest the trend that a higher
proportion of HPC families are linked to 1q24-25 when
the families have more affected members, especially in
families with male-to-male disease transmission. The
finding of an effect of number of affected individuals
within a family is consistent with the earlier findings by
Gro¨nberg et al. (1997).
Evidence of the HPC1 Locus and Estimate of Families
Linked to the HPC1 Locus in All Available HPC
Families
Since the above results provided some confirmation
for the HPC1 linkage, it was of interest to estimate the
overall evidence for the HPC1 locus and the proportion
of the families linked to theHPC1 locus for all available
families. This was done by combining the current 772
HPC families with the previous 79 HPC families ascer-
tained at Johns Hopkins University and 12 HPC families
from Sweden. Among all 863 HPC families available for
study, there was strong evidence for linkage in the 1q24-
25 region; the peak HLOD was 4.3 at D1S212 (P =
), with (1-LOD support interval68.59# 10 a = .09
.05–.15) (table 6). The evidence for linkage was greater
in the following subsets of families: the 550 families with
male-to-male disease transmission (peak HLOD = 5.65,
, , 1-LOD support interval .07–7P = 3.38# 10 a = .14
.21); the 306 families with early mean age (!65 years)
at diagnosis (peak HLOD = 5.23, ,7P = 9.22# 10
, 1-LOD support interval .09–.28); and the 224a = .18
families with five or more affected family members (peak
HLOD = 3.6, , , 1-LOD support5P = 4.67# 10 a = .12
interval .05–.22). There were statistical differences in the
proportions of families linked toHPC1 between the 550
families with male-to-male disease transmission and the
remaining 313 families ( , ); between the2x = 6.21 P = .01
306 families with early mean age at diagnosis and 557
families with late mean age at diagnosis ( ,2x = 6.30
). There was no statistical difference, however,P = .01
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Table 5
Parametric Multipoint Analysis
GROUP (NO. OF FAMILIES)
D1S452 D1S212 D1S466 D1S158 D1S422 D1S413
HLOD a HLOD a HLOD a HLOD a HLOD a HLOD a
Male-to-male transmission (491) 2.24 .11 2.56 .11 2.24 .11 1.81 .09 1.4 .08 1.45 .09
Non–male-to-male transmission (281) .00 .00 .00 .00 .00 .00 .00 .00 .00 .00 .00 .00
Age at diagnosis !65 years (263) .72 .09 1.32 .11 .59 .07 .14 .03 .09 .03 .21 .03
Age at diagnosis 65 years (509) .39 .04 .39 .04 .25 .03 .27 .03 .15 .03 .15 .03
5 affected family members per
family (174) .78 .08 1.11 .09 .87 .08 .66 .07 .48 .06 .92 .10
4 affected members per family (598) .34 .05 .42 .05 .11 .02 .02 .01 0 .00 0 .00
Male-to-male transmission:
Age at diagnosis !65 years (161) 1.27 .16 2.28 .19 1.22 .13 .45 .07 .68 .08 .5 .09
Age at diagnosis 65 (330) 1.08 .09 .79 .07 1.08 .09 1.39 .10 .9 .08 .96 .09
5 affected family members (141) 1.35 .13 2.01 .15 1.68 .14 1.25 .11 .9 .10 1.49 .14
4 affected family members (350) .91 .10 .71 .08 .68 .08 .61 .07 .53 .07 .24 .05
between 224 families with five or more affectedmembers
and 639 families with four or fewer affected members
( , ). The evidence for linkage was2x = 1.10 P = .29
strongest for the 66 families that met all three criteria:
male-to-male disease transmission, early mean age at di-
agnosis, and five or more affected family members. For
this group, the peak HLOD was 7.01 at D1S212 (P =
, , 1-LOD support interval .08–.53).93.31# 10 a = .39
Of these 66 families, 48 were from the current combined
analysis. For these 48 families, a peak HLOD of 2.25
was observed at the same marker ( ), withP = .001 a =
(1-LOD support interval .08–.53)..29
These results suggest an important role forHPC1 only
in a relatively small, highly defined subset of all families
affected by HPC. To put this result in perspective, it is
interesting to examine the results of previous linkage
analyses for another common cancer, breast cancer. In
the analyses performed by the Breast CancerConsortium
(Easton et al. 1993), it is clear that the primary evidence
of linkage to BRCA1, although much greater overall
than that observed forHPC1,was restricted to twomain
subsets of families: (1) those with breast and ovarian
cancer, and (2) among breast-cancer-only families, those
with large numbers of affected individuals diagnosed at
an early age. Breast-cancer-only families with average
ages of diagnoses 145 years or with fewer than four
affected individuals contributed little evidence of linkage
to BRCA1.
It is worth noting the large difference in the evidence
for HPC1 linkage between the data from the current
combined analysis and the data from Smith et al. (1996).
The peak multipoint HLOD in the current combined
analysis of 772 HPC families was 1.4, whereas the peak
HLOD (using the same model) in the study of Smith et
al. (91 HPC families) was 3.65. Even in the families that
met all three criteria (male-to-male disease transmission,
early mean age at diagnosis [!65 years], and five or more
affected family members), the 48 families with HPC
from the current study only had a peak HLOD of 2.25,
whereas the 18 such families from Smith et al. (1996)
had a peak HLOD of 5.53. Although this is most likely
attributable to numerous factors, differences in the char-
acteristics of the families in the two studies may be im-
portant. In the study by Smith et al., there was a higher
proportion of families with more than four affected
members or with a mean age at diagnosis of !65 years
(57.0% or 50.6%, respectively) than in the current study
(22.5% or 34.1%, respectively). Within the subgroup of
families with an average age of diagnosis of !65 years,
five or more affected members, and male-to-male trans-
mission, there were differences in power and informa-
tivity; for example, there was a higher average number
of affected individuals genotyped in the group of 18
families from the study by Smith et al. versus the 48
families from this combined analysis (3.8 vs. 3.3, re-
spectively), and the highest LOD scores observed in each
group varied considerably (2.61 vs. 1.20, respectively).
Other explanations for differences between the studies
might include differential use of PSA screening within
the study populations, which, in turn, could affect the
age at diagnosis and possibly the phenocopy rate. Fur-
thermore, the random variation of the proportions of
linked families in different study populations may con-
tribute to the difference. It is possible that in the initial
linkage study, the linked families were overrepresented
by chance, which led to the initial finding of linkage.
Overrepresentation of linked families, however, does not
happen often in replication studies by the trend of re-
gression to the mean.
Results of Parametric Multipoint Linkage Analyses, by
Use of Model B
Parametric multipoint linkage analyses by model B
were performed by the same procedure as that for model
A. Results for model B are summarized in table 7. In
general, the results were similar to those for model A,
although the LOD scores were always lower and the a
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Table 6
Parametric Multipoint Analysis in 772 Combined ICPCG and 91 Johns Hopkins University and Swedish Families Affected by HPC
GROUP (NO. OF FAMILIES)
D1S452 D1S212 D1S466 D1S158 D1S422 D1S413
HLOD a HLOD a HLOD a HLOD a HLOD a HLOD a
All (863): 2.98 .08 4.3 .09 3.41 .08 2.81 .07 2.57 .06 1.56 .07
Male-to-male transmission (550) 4.51 .13 5.65 .14 5.2 .13 4.78 .12 4.1 .11 2.78 .12
Age at diagnosis !65 years (306) 3.51 .15 5.23 .18 3.93 .14 3.03 .11 3.09 .12 2.06 .13
5 affected members per family
(224) 2.69 .11 3.6 .12 3.28 .11 3.11 .11 2.91 .11 1.94 .12
Families with all three criteria:
Current combined analysis (48) 1.29 .23 2.25 .29 1.09 .20 .15 .06 .21 .08 .24 .09
Smith et al. 1996 (18) 5.22 .61 5.23 .58 4.88 .52 5.53 .59 5.14 .58 2.76 .56
Total (66) 5.72 .37 7.01 .39 5.33 .31 3.85 .24 3.89 .26 1.91 .22
Table 7
Parametric Multipoint Analysis (LOD Assuming Heterogeneity, Model B)
STRATIFICATION (NO. OF FAMILIES)
D1S452 D1S212 D1S466 D1S158 D1S422 D1S413
HLOD a HLOD a HLOD a HLOD a HLOD a HLOD a
All (772) .31 .08 .50 .10 .39 .09 .17 .05 .17 .06 .39 .10
Male-to-male transmission (491) .84 .17 1.50 .22 1.61 .23 1.02 .17 .54 .13 .83 .18
Non–male-to-male transmission (281) .00 .00 .00 .00 .00 .00 .00 .00 .00 .00 .00 .00
Onset at age !65 years (263) .31 .17 .50 .16 .39 .06 .17 .00 .17 .00 .39 .05
Onset at age 65 years (509) .00 .00 .04 .04 .33 .11 .44 .12 .06 .16 .43 .14
5 affected family members (274) .44 .16 .90 .22 1.26 .26 .93 .21 .45 .15 .54 .19
4 affected family members (598) .02 .03 .02 .02 .00 .00 .00 .00 .00 .00 .03 .04
Male-to-male transmission, age at
onset !65 years (161) .84 .23 .92 .23 .23 .12 .00 .01 .00 .00 .04 .06
Male-to-male transmission, 5
affected family members (141) .61 .20 1.33 .30 1.82 .35 1.31 .28 .70 .22 .90 .27
Male-to-male transmission, age at
onset !65 years, 5 affected fam-
ily members (48) .52 .25 .86 .33 .41 .22 .02 .05 .00 .01 .03 .06
value was always higher than those for model A. These
differences may be explained by the genotypic pene-
trances specified in the two models. The penetrance val-
ues specified by model A were such that affected indi-
viduals had a very high probability of being gene carriers
(penetrance ratios of gene carriers to noncarriers were
high); thus, they are very informative for linkage. This
does not seem to represent families with HPC in general
but may represent a subset of HPC families, which is
certainly appropriate when combined with the assump-
tion of heterogeneity. The penetrance ratios between
gene carriers and noncarriers specified in model B were
lower; thus, affected individuals are not very informa-
tive. This causes the LOD score to approach 0. Another
explanation for the lower LOD scores for model B could
be model misspecification. If model A were closer to
truth than model B is, then model B would overestimate
the recombination fraction, which decreases the LOD
score. Also, since the recombination fraction and a are
positively correlated, an increased estimate of recom-
bination fraction would cause the a value to be
increased.
Results of Nonparametric Multipoint Linkage Analyses
Nonparametric analyses were performed in parallel to
the parametric analyses. Results are shown in table 8.
There was no evidence for linkage of a prostate can-
cer–susceptibility locus to the 1q24-25 region in the
combined 772 HPC families; the NPL scores were neg-
ative for all six markers. The NPL scores were negative
in general in all the stratified analyses, except in the
subset of 491 families with evidence for male-to-male
disease transmission (NPL = 0.32 at D1S452) and in the
48 families that met all three criteria: male-to-male dis-
ease transmission, mean age at diagnosis !65 years, and
five or more affected family members (NPL = 0.14 at
D1S452). There are two possible explanations for the
difference between the parametric and nonparametric
analyses. First, the NPL scores were calculated by
weighting each family equally, regardless of the size
(number of informative meioses) of the families. Second,
and perhaps more important, nonparametric analyses in
general have lower power (compared with the para-
metric analyses) to detect linkage when the model of the
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Table 8
Nonparametric Multipoint Linkage Analysis (NPL Scores)
STRATIFICATION (NO. OF FAMILIES)
NPL SCORES AT MARKER
D1S452 D1S212 D1S466 D1S158 D1S422 D1S413
All (772) 1.06 1.57 1.83 2.68 1.85 1.12
Male-to-male transmission* (491) .32 .15 .19 .95 .23 .05
Non–male-to-male transmission (281) 2.18 2.40 2.78 3.19 2.76 1.93
Age at onset !65 years (263) .87 1.33 1.57 2.28 1.73 1.13
Age at onset 65 years (509) .68 .98 1.13 1.66 1.04 .57
5 affected family members (274) .90 1.90 1.40 1.81 .93 .60
4 affected family members (598) .72 .76 1.33 2.07 1.60 .95
Male-to-male transmission, age at onset !65 years (161) .07 .27 .49 .98 .50 .44
Male-to-male transmission, 5 affected family members (141) .13 .80 .49 1.03 .40 .08
Male-to-male transmission, age at onset !65 years, 5 af-
fected family members (48) .14 .10 .51 1.52 .82 .86
disease transmission is approximately correct (Green-
berg et al. 1998). (Importantly, on the basis of theoretical
and simulation studies [Hodge and Elston 1994; Green-
berg et al. 1998], the use of an incorrectly specified
model in the parametric analyses will not increase the
false-positive rate as long as marker allele frequencies
are correctly specified.) Additionally, analyses assuming
heterogeneity can be readily implemented in the para-
metric analysis, which greatly increases the power to
detect linkage when there is a substantial degree of het-
erogeneity. Nonparametric analyses, however, do not
have this property. An examination of the LOD scores
and the NPL scores for each family in the group of 48
families that met all three criteria illustrates this point.
In this group, 21 families had positive LOD scores; all
but one of these 21 also had a positive NPL score (the
remaining family had a NPL score of -0.06). Similarly,
among the remaining 27 families with negative LOD
scores, all but two had negative NPL scores. Thus, both
approaches would seem to provide similar evidence for
linkage. In spite of this concordance for the individual
families, the summary statistics gave rather distinct re-
sults: an HLOD of 2.25 and a NPL score of .10 in
this group. It is worth noting that the summary LOD
score assuming homogeneity is highly negative (16.41)
for this group, which is not surprising, since there is still
a significant proportion of heterogeneity even in this
subset. This further emphasizes the need to perform the
analysis assuming heterogeneity.
Summary and Conclusion
Overall weak evidence of linkage to HPC1 was ob-
served in a combined international study population of
772 HPC families, with the estimated proportion of
linked families being 6%. Stronger evidence of linkage
was observed in subsets of families, varying by the pres-
ence or absence of apparent male-to-male disease trans-
mission, mean age at diagnosis, and number of affected
individuals. We did not correct P values for having mul-
tiple tests (two genetic models and multiple stratification
of the data set) in reporting the significance levels of the
linkage results for the following two reasons. First, the
current analysis is a replication study; we primarily used
the same genetic model (model A) and the same strati-
fication as implemented in the initial studies. Second, the
two models are related and thus are not independent.
In fact, these two models are very similar: both assume
a dominant mode of inheritance and a rare disease allele.
We applied model B in this analysis mainly to investigate
the impact of a more general model (estimates from seg-
regation analyses) on the LOD scores. As expected, this
model is less informative because it allows higher phe-
nocopy rates and lower penetrances.
Although these data support the linkage toHPC1, this
study indicates that most HPC families will not provide
evidence for this locus. Further, it suggests that efforts
for gene identification should focus on the restricted sub-
set of HPC families characterized by male-to-male dis-
ease transmission and by large numbers of affected in-
dividuals with an early age at diagnosis. This inter-
national study suggests that such families represent only
∼8% of families associated with multiplex prostate
cancer.
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